The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction

azelaprag (BGE-105) - BioAge Labs

https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ADA25&id=1789

PAUL RUBIN; SHIJUN YAN; CLAUDIA PORTILLO; YAN WANG; MATTHEW BANICKI; MARY COCHRAN; ANDREW BANICKI; GABRIEL GUERRERO; CARL RODRIGUEZ; ALLISON RITTER; SAMANTHA COWDIN; CHRISTOPHER PATIL; JUSTIN REBO; RUSTY MONTGOMERY; ERIC MORGEN; KRISTEN FORTNEY

Mar 30, 2025